---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-122541"
form_type: "8-K"
ticker: "NMTC"
cik: "0001500198"
company_name: "NEUROONE MEDICAL TECHNOLOGIES Corp"
filed_at: "2025-12-17T23:59:59+00:00"
generated_at: "2026-05-16T12:55:03.012647+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# NeuroOne reports Q4 product revenue of $2.7M (+907% YoY); full-year loss narrows 71%

## Summary
- Product revenue $2.7M in Q4 FY2025, up 907% YoY; full year product revenue $9.1M, up 163% YoY.
- Product gross margin improved to 55.8% in Q4 and 56.5% for FY2025, up from 31.3% in FY2024.
- Net loss improved 71% to $3.6M ($0.09/share) for FY2025; Q4 net loss $1.6M ($0.03/share) vs $3.4M ($0.11) YoY.
- FDA 510(k) clearance for OneRF Trigeminal Nerve Ablation System; first two trigeminal neuralgia patients treated.
- Cash & equivalents $6.6M (up from $1.5M); no debt; funded through fiscal 2026.

## SEC filing metadata
- accession: 0001213900-25-122541
- form_type: 8-K
- ticker: NMTC
- cik: 0001500198
- company_name: NEUROONE MEDICAL TECHNOLOGIES Corp
- filed_at: 2025-12-17T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1500198/000121390025122541/0001213900-25-122541-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1500198/000121390025122541/ea0269921-8k_neuroone.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-122541
- JSON: https://secwatch.observer/filing/0001213900-25-122541.json
- Plain text: https://secwatch.observer/filing/0001213900-25-122541.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.